The Potential Benefits of Electronic Cigarettes: A Long-term Study

Sep.05.2022
The Potential Benefits of Electronic Cigarettes: A Long-term Study
A long-term experiment shows e-cigarette usage can reduce the harm of smoking compared to traditional cigarettes.

A long-term experiment involving hundreds of smokers was conducted, in which some continued to smoke, while others switched completely to e-cigarettes, and some quit nicotine altogether. Analysis of biological markers for potential harm indicated that completely switching to e-cigarettes can reduce the harm associated with smoking.


In 1798, Dr. Benjamin Rush was one of the earliest people to suggest that smoking could lead to cancer. By the 1920s, over a thousand cases of lung cancer had been reported. Meanwhile, inventors began looking for ways to reduce the risks of tobacco. In 1927, American Joseph Robinson patented a device that produced electronic vapor and proposed the safe inhalation of vapors containing medicinal compounds without being burned. This idea remained on paper.


The modern e-cigarette did not appear until 2003, when it was developed by Chinese pharmacist Hon Lik. Since then, its popularity has gradually increased. Today, lung cancer is the second most common cancer in the world, with smoking being the main cause of its development (in 85% of cases). In Russia, the incidence and mortality rates of lung cancer also rank second, causing 27,000 deaths each year.


Since 2019, the number of smokers in Russia has been declining gradually. According to VTsIOM, approximately one-third of the population in urban areas smoke, with the majority of them smoking more than a pack a day using traditional methods such as cigarettes, cigars, roll-your-own and hookah. However, there is a rapid increase in the popularity of e-cigarettes.


Electronic cigarettes entered Europe, the United States, and Russia around 2007. At that time, there were no studies on the effects of these new products on the body, and as a result, health organizations and doctors were unsure how to regulate their circulation and provide advice to people. Today, the global electronic cigarette market is valued at over $18 billion. Analysis shows that smoking not only wastes money but also has a negative impact on health. Smokers have a death rate over three times higher than non-smokers after the age of 65.


Alternative products to traditional cigarettes are becoming increasingly popular worldwide. Many have successfully quit smoking with their help. For those who are not ready or unable to quit smoking entirely, electronic cigarettes can reduce the amount of toxins inhaled. Fortunately, over the past 20 years, there have been enough medical observations and scientific studies to conclude that high-quality, verified electronic cigarettes can reduce harm to health and help overcome addiction.


One method of monitoring the effects of smoking on the body is to track exposure biomarkers (BoE) and potential harm (BoPH) associated with oxidative stress, cancer, cardiovascular disease, and respiratory illness.


A new study on biomarkers has indicated that completely switching from traditional cigarettes to alternative smoking products can significantly reduce the harm caused by smoking.


In the UK, scientists have decided to examine the changes in biomarkers of individuals who have quit smoking or switched to e-cigarettes completely over a few months. The transition to heating systems is equivalent to quitting smoking completely for some biomarkers. The results have been published in the peer-reviewed medical journal, "Internal Medicine and Emergency Medicine Journal".


The study involved adults aged 23 to 55 who had been smoking for at least 5 years and were smoking between 10-30 non-menthol cigarettes per day at the start of the study. They were all healthy. Participants who wished to continue smoking were randomly divided into two groups: one group continued to smoke regular cigarettes, while the second group was given electronic cigarettes. At the time of publication, 59 people continued to smoke, 127 people switched to electronic cigarettes, 109 people stopped smoking altogether, and 37 people were in the control group. To monitor compliance, participants were tested for CEVal biomarkers.


It is worth noting that participants who switched to e-cigarettes prior to the experiment had slightly higher consumption rates compared to traditional cigarette users (with one e-cigarette deemed equivalent to one cigarette) and those who continued smoking. However, this consumption rate remained stable throughout all six months of the study. The results indicate that switching to e-cigarettes led to statistically significant changes in biological markers, with some even approaching data from the group who quit smoking altogether. Canadian scientists have discovered that smokers and those with chronic obstructive pulmonary disease show increased entry of SARS-CoV-2 into their epithelial cells.


Biomarkers for oxidative stress in the body (8-Epi-PGF2α Type III) were significantly reduced, and white blood cell count decreased (indicating a presence of inflammation). At the same time, indicators of lung and vascular health improved, as did the level of high-density lipoprotein cholesterol, which suggests a lower risk for cardiovascular disease. Most importantly, those who switched to e-cigarettes saw a decrease of about half in NNAL levels (a lung cancer risk indicator) to 115.7 ng/day. Of course, the decrease was even greater in those who quit smoking entirely, going from smokers' levels (221.94 ng/day) to four times less (59.09 ng/day). However, in order to reach the levels of those who never smoked, the decrease must be 20 times less (to 11.54 ng/day).


It’s important to remember that there are different alternatives to traditional smoking, and they are all quite different from each other. Electronic cigarettes or e-cigarettes use a special liquid that produces thick vapor. The primary ingredients in this liquid are glycerin or propylene glycol, which are compounds used in smoke machines. Studies have shown that these ingredients do not cause lung inflammation, but they do cause dryness. The e-liquid used in e-cigarettes can contain nicotine (at varying concentrations) or it can be nicotine-free.


Nicotine has been proven to be addictive, but the main harm comes from other toxic compounds formed during the combustion of tobacco - there are about 6,000 of them. Some scientists believe that these compounds increase the risk of addiction to nicotine.


Disclaimer: 1. The content of this article is compiled from third-party information and is only for industry exchange and learning. 2. This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity and accuracy of the content of the article. The compilation of this article is only for industry exchange and research. 3. Due to the limited level of compilation, the compiled article may not express the same meaning as the original article, please refer to the original article for accuracy. 4. For any domestic, Hong Kong, Macao, Taiwan, or foreign expressions and positions, 2FIRSTS is fully in line with the Chinese government. 5. The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
Special Report|From CrossBar 20K to 6-Methyl Nicotine KUMI: Two Routes Into U.S. State Vape Directories?
Special Report|From CrossBar 20K to 6-Methyl Nicotine KUMI: Two Routes Into U.S. State Vape Directories?
Several U.S. states have incorporated the September 9, 2020 PMTA filing deadline into eligibility rules for certain vaping products. CrossBar 20K drew attention after appearing on Pennsylvania's 163-entry directory. A broader 2Firsts investigation found that related registration businesses also listed KUMI and CROSSBAR SIX products, with 171 KUMI-related entries across Louisiana, Nebraska and Wisconsin. Corporate records link Scott Silverman to Blue Nine LLC and VR Products I LLC. PMTA compliance expert Mr. K said historical applications and nicotine-analogue products may offer two different approaches to state-directory access.
Regulations
Oct.26
Philippines BIR Steps Up Illicit Vape Enforcement Ahead of Christmas Shopping
Philippines BIR Steps Up Illicit Vape Enforcement Ahead of Christmas Shopping
The Philippines’ Bureau of Internal Revenue is intensifying enforcement against illicit vape and tobacco products ahead of the Christmas shopping season, directing regional and enforcement offices to strengthen monitoring of production sites, warehouses, distribution channels and retail outlets. The BIR destroyed 240,550 illicit vape products in August with an estimated tax liability of about PHP1.53 billion. A nationwide tax-compliance operation in July also inspected 3,590 businesses involved in tobacco and vapor products.
Regulations
Sep.17 by 2Firsts Perspectives
GSTHR Estimates 200 Million People Use Non-Combustible Nicotine Products as 28 Countries Show Rising Use Alongside Falling Smoking Rates
GSTHR Estimates 200 Million People Use Non-Combustible Nicotine Products as 28 Countries Show Rising Use Alongside Falling Smoking Rates
The Global State of Tobacco Harm Reduction, a project operated by Knowledge·Action·Change, estimates that about 200 million people worldwide use non-combustible nicotine products including vapes, heated tobacco, nicotine pouches and snus. Its 2026 report says use of these products rose alongside declining smoking rates in 28 countries it analyzed. The data do not establish that all 200 million users have quit smoking, nor do they prove a direct causal relationship. GSTHR also says regulatory restrictions on the products continue to expand in many markets.
Sep.10
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
At the 2026 New Approaches Summit in New York, former FDA Center for Tobacco Products Director Mitch Zeller called for the tobacco harm reduction debate to shift from the traditional “end game” toward defining a desired “end state.” He also highlighted unresolved concerns around dual use, argued that biomarkers of exposure may be more meaningful than cigarettes-per-day in assessing risk reduction, and said nicotine misperceptions remain a major barrier to public health progress.
Sep.25
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
The U.S. Department of Health and Human Services has named Bret Koplow permanent director of the FDA’s Center for Tobacco Products, ending his period as acting chief. Koplow has spent years working on tobacco regulation, law and policy inside the FDA and, while serving as acting director, pushed for faster PMTA reviews and nicotine pouch review pilots. HHS also said CTP will prioritize innovation and access to less harmful alternatives for adult smokers while continuing efforts to protect youth.
Sep.09